Clinical doses of fluoxetine and cerebral blood flow in healthy volunteers
Abstract Rationale: Of the specific serotonin reuptake inhibitors (SSRIs), fluoxetine is perhaps the most widely used. Anecdotal reports, mostly in the non-medical press, have suggested that it may positively affect psychological functioning and enhance quality of life in the absence of overt psychi...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
1999 |
|---|
| Umfang: |
5 |
|---|
| Reproduktion: |
Springer Online Journal Archives 1860-2002 |
|---|---|
| Übergeordnetes Werk: |
in: Psychopharmacology - 1959, 143(1999) vom: Jan., Seite 24-28 |
| Übergeordnetes Werk: |
volume:143 ; year:1999 ; month:01 ; pages:24-28 ; extent:5 |
| Links: |
|---|
| Katalog-ID: |
NLEJ200735004 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ200735004 | ||
| 003 | DE-627 | ||
| 005 | 20210706055915.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 070527s1999 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)NLEJ200735004 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Clinical doses of fluoxetine and cerebral blood flow in healthy volunteers |
| 264 | 1 | |c 1999 | |
| 300 | |a 5 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Abstract Rationale: Of the specific serotonin reuptake inhibitors (SSRIs), fluoxetine is perhaps the most widely used. Anecdotal reports, mostly in the non-medical press, have suggested that it may positively affect psychological functioning and enhance quality of life in the absence of overt psychiatric disorder. Such widespread use is not supported by scientific data. Objective: This prospective single blind study examined the effects of long term administration of clinical doses of fluoxetine on cerebral blood flow (CBF) in healthy volunteers. Methods: Fifteen healthy subjects were examined by Tc99m HMPAO SPECT after 2 weeks of placebo administration and then after 6 weeks of fluoxetine, administered at 20 mg per day. Blood for fluoxetine and norfluoxetine plasma levels was drawn to ensure compliance. Tc99m HMPAO uptake was analyzed by the region of interest approach, normalized to the cerebellum, and by statistical parametric mapping (SPM). Results: No statistically significant differences between the two conditions were detected by both techniques. Correlation analysis between fluoxetine and norfluoxetine plasma levels and rCBF yielded no statistically significant values. Conclusion: Our findings suggest a differential effect of fluoxetine on CBF under the following conditions: (i) mental health versus psychiatric illness; (ii) acute versus long term administration. Our findings further emphasize the importance of longitudinal studies in elucidating the physiology of the normal brain as well as the pathophysiology of psychiatric disorders. | ||
| 533 | |f Springer Online Journal Archives 1860-2002 | ||
| 700 | 1 | |a Bonne, O. |4 oth | |
| 700 | 1 | |a Krausz, Yodphat |4 oth | |
| 700 | 1 | |a Aharon, Yitzhak |4 oth | |
| 700 | 1 | |a Gelfin, Yevgenia |4 oth | |
| 700 | 1 | |a Chisin, Roland |4 oth | |
| 700 | 1 | |a Lerer, Bernard |4 oth | |
| 773 | 0 | 8 | |i in |t Psychopharmacology |d 1959 |g 143(1999) vom: Jan., Seite 24-28 |w (DE-627)NLEJ188990615 |w (DE-600)2066933-1 |x 1432-2072 |7 nnns |
| 773 | 1 | 8 | |g volume:143 |g year:1999 |g month:01 |g pages:24-28 |g extent:5 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s002130050915 |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-SOJ | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 143 |j 1999 |c 1 |h 24-28 |g 5 | ||
| matchkey_str |
article:14322072:1999----::lncloeofuxtnadeerllofoih |
|---|---|
| hierarchy_sort_str |
1999 |
| publishDate |
1999 |
| allfields |
(DE-627)NLEJ200735004 DE-627 ger DE-627 rakwb eng Clinical doses of fluoxetine and cerebral blood flow in healthy volunteers 1999 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract Rationale: Of the specific serotonin reuptake inhibitors (SSRIs), fluoxetine is perhaps the most widely used. Anecdotal reports, mostly in the non-medical press, have suggested that it may positively affect psychological functioning and enhance quality of life in the absence of overt psychiatric disorder. Such widespread use is not supported by scientific data. Objective: This prospective single blind study examined the effects of long term administration of clinical doses of fluoxetine on cerebral blood flow (CBF) in healthy volunteers. Methods: Fifteen healthy subjects were examined by Tc99m HMPAO SPECT after 2 weeks of placebo administration and then after 6 weeks of fluoxetine, administered at 20 mg per day. Blood for fluoxetine and norfluoxetine plasma levels was drawn to ensure compliance. Tc99m HMPAO uptake was analyzed by the region of interest approach, normalized to the cerebellum, and by statistical parametric mapping (SPM). Results: No statistically significant differences between the two conditions were detected by both techniques. Correlation analysis between fluoxetine and norfluoxetine plasma levels and rCBF yielded no statistically significant values. Conclusion: Our findings suggest a differential effect of fluoxetine on CBF under the following conditions: (i) mental health versus psychiatric illness; (ii) acute versus long term administration. Our findings further emphasize the importance of longitudinal studies in elucidating the physiology of the normal brain as well as the pathophysiology of psychiatric disorders. Springer Online Journal Archives 1860-2002 Bonne, O. oth Krausz, Yodphat oth Aharon, Yitzhak oth Gelfin, Yevgenia oth Chisin, Roland oth Lerer, Bernard oth in Psychopharmacology 1959 143(1999) vom: Jan., Seite 24-28 (DE-627)NLEJ188990615 (DE-600)2066933-1 1432-2072 nnns volume:143 year:1999 month:01 pages:24-28 extent:5 http://dx.doi.org/10.1007/s002130050915 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 143 1999 1 24-28 5 |
| spelling |
(DE-627)NLEJ200735004 DE-627 ger DE-627 rakwb eng Clinical doses of fluoxetine and cerebral blood flow in healthy volunteers 1999 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract Rationale: Of the specific serotonin reuptake inhibitors (SSRIs), fluoxetine is perhaps the most widely used. Anecdotal reports, mostly in the non-medical press, have suggested that it may positively affect psychological functioning and enhance quality of life in the absence of overt psychiatric disorder. Such widespread use is not supported by scientific data. Objective: This prospective single blind study examined the effects of long term administration of clinical doses of fluoxetine on cerebral blood flow (CBF) in healthy volunteers. Methods: Fifteen healthy subjects were examined by Tc99m HMPAO SPECT after 2 weeks of placebo administration and then after 6 weeks of fluoxetine, administered at 20 mg per day. Blood for fluoxetine and norfluoxetine plasma levels was drawn to ensure compliance. Tc99m HMPAO uptake was analyzed by the region of interest approach, normalized to the cerebellum, and by statistical parametric mapping (SPM). Results: No statistically significant differences between the two conditions were detected by both techniques. Correlation analysis between fluoxetine and norfluoxetine plasma levels and rCBF yielded no statistically significant values. Conclusion: Our findings suggest a differential effect of fluoxetine on CBF under the following conditions: (i) mental health versus psychiatric illness; (ii) acute versus long term administration. Our findings further emphasize the importance of longitudinal studies in elucidating the physiology of the normal brain as well as the pathophysiology of psychiatric disorders. Springer Online Journal Archives 1860-2002 Bonne, O. oth Krausz, Yodphat oth Aharon, Yitzhak oth Gelfin, Yevgenia oth Chisin, Roland oth Lerer, Bernard oth in Psychopharmacology 1959 143(1999) vom: Jan., Seite 24-28 (DE-627)NLEJ188990615 (DE-600)2066933-1 1432-2072 nnns volume:143 year:1999 month:01 pages:24-28 extent:5 http://dx.doi.org/10.1007/s002130050915 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 143 1999 1 24-28 5 |
| allfields_unstemmed |
(DE-627)NLEJ200735004 DE-627 ger DE-627 rakwb eng Clinical doses of fluoxetine and cerebral blood flow in healthy volunteers 1999 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract Rationale: Of the specific serotonin reuptake inhibitors (SSRIs), fluoxetine is perhaps the most widely used. Anecdotal reports, mostly in the non-medical press, have suggested that it may positively affect psychological functioning and enhance quality of life in the absence of overt psychiatric disorder. Such widespread use is not supported by scientific data. Objective: This prospective single blind study examined the effects of long term administration of clinical doses of fluoxetine on cerebral blood flow (CBF) in healthy volunteers. Methods: Fifteen healthy subjects were examined by Tc99m HMPAO SPECT after 2 weeks of placebo administration and then after 6 weeks of fluoxetine, administered at 20 mg per day. Blood for fluoxetine and norfluoxetine plasma levels was drawn to ensure compliance. Tc99m HMPAO uptake was analyzed by the region of interest approach, normalized to the cerebellum, and by statistical parametric mapping (SPM). Results: No statistically significant differences between the two conditions were detected by both techniques. Correlation analysis between fluoxetine and norfluoxetine plasma levels and rCBF yielded no statistically significant values. Conclusion: Our findings suggest a differential effect of fluoxetine on CBF under the following conditions: (i) mental health versus psychiatric illness; (ii) acute versus long term administration. Our findings further emphasize the importance of longitudinal studies in elucidating the physiology of the normal brain as well as the pathophysiology of psychiatric disorders. Springer Online Journal Archives 1860-2002 Bonne, O. oth Krausz, Yodphat oth Aharon, Yitzhak oth Gelfin, Yevgenia oth Chisin, Roland oth Lerer, Bernard oth in Psychopharmacology 1959 143(1999) vom: Jan., Seite 24-28 (DE-627)NLEJ188990615 (DE-600)2066933-1 1432-2072 nnns volume:143 year:1999 month:01 pages:24-28 extent:5 http://dx.doi.org/10.1007/s002130050915 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 143 1999 1 24-28 5 |
| allfieldsGer |
(DE-627)NLEJ200735004 DE-627 ger DE-627 rakwb eng Clinical doses of fluoxetine and cerebral blood flow in healthy volunteers 1999 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract Rationale: Of the specific serotonin reuptake inhibitors (SSRIs), fluoxetine is perhaps the most widely used. Anecdotal reports, mostly in the non-medical press, have suggested that it may positively affect psychological functioning and enhance quality of life in the absence of overt psychiatric disorder. Such widespread use is not supported by scientific data. Objective: This prospective single blind study examined the effects of long term administration of clinical doses of fluoxetine on cerebral blood flow (CBF) in healthy volunteers. Methods: Fifteen healthy subjects were examined by Tc99m HMPAO SPECT after 2 weeks of placebo administration and then after 6 weeks of fluoxetine, administered at 20 mg per day. Blood for fluoxetine and norfluoxetine plasma levels was drawn to ensure compliance. Tc99m HMPAO uptake was analyzed by the region of interest approach, normalized to the cerebellum, and by statistical parametric mapping (SPM). Results: No statistically significant differences between the two conditions were detected by both techniques. Correlation analysis between fluoxetine and norfluoxetine plasma levels and rCBF yielded no statistically significant values. Conclusion: Our findings suggest a differential effect of fluoxetine on CBF under the following conditions: (i) mental health versus psychiatric illness; (ii) acute versus long term administration. Our findings further emphasize the importance of longitudinal studies in elucidating the physiology of the normal brain as well as the pathophysiology of psychiatric disorders. Springer Online Journal Archives 1860-2002 Bonne, O. oth Krausz, Yodphat oth Aharon, Yitzhak oth Gelfin, Yevgenia oth Chisin, Roland oth Lerer, Bernard oth in Psychopharmacology 1959 143(1999) vom: Jan., Seite 24-28 (DE-627)NLEJ188990615 (DE-600)2066933-1 1432-2072 nnns volume:143 year:1999 month:01 pages:24-28 extent:5 http://dx.doi.org/10.1007/s002130050915 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 143 1999 1 24-28 5 |
| allfieldsSound |
(DE-627)NLEJ200735004 DE-627 ger DE-627 rakwb eng Clinical doses of fluoxetine and cerebral blood flow in healthy volunteers 1999 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract Rationale: Of the specific serotonin reuptake inhibitors (SSRIs), fluoxetine is perhaps the most widely used. Anecdotal reports, mostly in the non-medical press, have suggested that it may positively affect psychological functioning and enhance quality of life in the absence of overt psychiatric disorder. Such widespread use is not supported by scientific data. Objective: This prospective single blind study examined the effects of long term administration of clinical doses of fluoxetine on cerebral blood flow (CBF) in healthy volunteers. Methods: Fifteen healthy subjects were examined by Tc99m HMPAO SPECT after 2 weeks of placebo administration and then after 6 weeks of fluoxetine, administered at 20 mg per day. Blood for fluoxetine and norfluoxetine plasma levels was drawn to ensure compliance. Tc99m HMPAO uptake was analyzed by the region of interest approach, normalized to the cerebellum, and by statistical parametric mapping (SPM). Results: No statistically significant differences between the two conditions were detected by both techniques. Correlation analysis between fluoxetine and norfluoxetine plasma levels and rCBF yielded no statistically significant values. Conclusion: Our findings suggest a differential effect of fluoxetine on CBF under the following conditions: (i) mental health versus psychiatric illness; (ii) acute versus long term administration. Our findings further emphasize the importance of longitudinal studies in elucidating the physiology of the normal brain as well as the pathophysiology of psychiatric disorders. Springer Online Journal Archives 1860-2002 Bonne, O. oth Krausz, Yodphat oth Aharon, Yitzhak oth Gelfin, Yevgenia oth Chisin, Roland oth Lerer, Bernard oth in Psychopharmacology 1959 143(1999) vom: Jan., Seite 24-28 (DE-627)NLEJ188990615 (DE-600)2066933-1 1432-2072 nnns volume:143 year:1999 month:01 pages:24-28 extent:5 http://dx.doi.org/10.1007/s002130050915 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 143 1999 1 24-28 5 |
| language |
English |
| source |
in Psychopharmacology 143(1999) vom: Jan., Seite 24-28 volume:143 year:1999 month:01 pages:24-28 extent:5 |
| sourceStr |
in Psychopharmacology 143(1999) vom: Jan., Seite 24-28 volume:143 year:1999 month:01 pages:24-28 extent:5 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| isfreeaccess_bool |
false |
| container_title |
Psychopharmacology |
| authorswithroles_txt_mv |
Bonne, O. @@oth@@ Krausz, Yodphat @@oth@@ Aharon, Yitzhak @@oth@@ Gelfin, Yevgenia @@oth@@ Chisin, Roland @@oth@@ Lerer, Bernard @@oth@@ |
| publishDateDaySort_date |
1999-01-01T00:00:00Z |
| hierarchy_top_id |
NLEJ188990615 |
| id |
NLEJ200735004 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ200735004</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20210706055915.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070527s1999 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ200735004</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Clinical doses of fluoxetine and cerebral blood flow in healthy volunteers</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1999</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">5</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Rationale: Of the specific serotonin reuptake inhibitors (SSRIs), fluoxetine is perhaps the most widely used. Anecdotal reports, mostly in the non-medical press, have suggested that it may positively affect psychological functioning and enhance quality of life in the absence of overt psychiatric disorder. Such widespread use is not supported by scientific data. Objective: This prospective single blind study examined the effects of long term administration of clinical doses of fluoxetine on cerebral blood flow (CBF) in healthy volunteers. Methods: Fifteen healthy subjects were examined by Tc99m HMPAO SPECT after 2 weeks of placebo administration and then after 6 weeks of fluoxetine, administered at 20 mg per day. Blood for fluoxetine and norfluoxetine plasma levels was drawn to ensure compliance. Tc99m HMPAO uptake was analyzed by the region of interest approach, normalized to the cerebellum, and by statistical parametric mapping (SPM). Results: No statistically significant differences between the two conditions were detected by both techniques. Correlation analysis between fluoxetine and norfluoxetine plasma levels and rCBF yielded no statistically significant values. Conclusion: Our findings suggest a differential effect of fluoxetine on CBF under the following conditions: (i) mental health versus psychiatric illness; (ii) acute versus long term administration. Our findings further emphasize the importance of longitudinal studies in elucidating the physiology of the normal brain as well as the pathophysiology of psychiatric disorders.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bonne, O.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Krausz, Yodphat</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Aharon, Yitzhak</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gelfin, Yevgenia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chisin, Roland</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lerer, Bernard</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">Psychopharmacology</subfield><subfield code="d">1959</subfield><subfield code="g">143(1999) vom: Jan., Seite 24-28</subfield><subfield code="w">(DE-627)NLEJ188990615</subfield><subfield code="w">(DE-600)2066933-1</subfield><subfield code="x">1432-2072</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:143</subfield><subfield code="g">year:1999</subfield><subfield code="g">month:01</subfield><subfield code="g">pages:24-28</subfield><subfield code="g">extent:5</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/s002130050915</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">143</subfield><subfield code="j">1999</subfield><subfield code="c">1</subfield><subfield code="h">24-28</subfield><subfield code="g">5</subfield></datafield></record></collection>
|
| series2 |
Springer Online Journal Archives 1860-2002 |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ188990615 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| collection |
NL |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1432-2072 |
| topic_title |
Clinical doses of fluoxetine and cerebral blood flow in healthy volunteers |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
o b ob y k yk y a ya y g yg r c rc b l bl |
| hierarchy_parent_title |
Psychopharmacology |
| hierarchy_parent_id |
NLEJ188990615 |
| hierarchy_top_title |
Psychopharmacology |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ188990615 (DE-600)2066933-1 |
| title |
Clinical doses of fluoxetine and cerebral blood flow in healthy volunteers |
| spellingShingle |
Clinical doses of fluoxetine and cerebral blood flow in healthy volunteers |
| ctrlnum |
(DE-627)NLEJ200735004 |
| title_full |
Clinical doses of fluoxetine and cerebral blood flow in healthy volunteers |
| journal |
Psychopharmacology |
| journalStr |
Psychopharmacology |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
1999 |
| contenttype_str_mv |
zzz |
| container_start_page |
24 |
| container_volume |
143 |
| physical |
5 |
| format_se |
Elektronische Aufsätze |
| title_sort |
clinical doses of fluoxetine and cerebral blood flow in healthy volunteers |
| title_auth |
Clinical doses of fluoxetine and cerebral blood flow in healthy volunteers |
| abstract |
Abstract Rationale: Of the specific serotonin reuptake inhibitors (SSRIs), fluoxetine is perhaps the most widely used. Anecdotal reports, mostly in the non-medical press, have suggested that it may positively affect psychological functioning and enhance quality of life in the absence of overt psychiatric disorder. Such widespread use is not supported by scientific data. Objective: This prospective single blind study examined the effects of long term administration of clinical doses of fluoxetine on cerebral blood flow (CBF) in healthy volunteers. Methods: Fifteen healthy subjects were examined by Tc99m HMPAO SPECT after 2 weeks of placebo administration and then after 6 weeks of fluoxetine, administered at 20 mg per day. Blood for fluoxetine and norfluoxetine plasma levels was drawn to ensure compliance. Tc99m HMPAO uptake was analyzed by the region of interest approach, normalized to the cerebellum, and by statistical parametric mapping (SPM). Results: No statistically significant differences between the two conditions were detected by both techniques. Correlation analysis between fluoxetine and norfluoxetine plasma levels and rCBF yielded no statistically significant values. Conclusion: Our findings suggest a differential effect of fluoxetine on CBF under the following conditions: (i) mental health versus psychiatric illness; (ii) acute versus long term administration. Our findings further emphasize the importance of longitudinal studies in elucidating the physiology of the normal brain as well as the pathophysiology of psychiatric disorders. |
| abstractGer |
Abstract Rationale: Of the specific serotonin reuptake inhibitors (SSRIs), fluoxetine is perhaps the most widely used. Anecdotal reports, mostly in the non-medical press, have suggested that it may positively affect psychological functioning and enhance quality of life in the absence of overt psychiatric disorder. Such widespread use is not supported by scientific data. Objective: This prospective single blind study examined the effects of long term administration of clinical doses of fluoxetine on cerebral blood flow (CBF) in healthy volunteers. Methods: Fifteen healthy subjects were examined by Tc99m HMPAO SPECT after 2 weeks of placebo administration and then after 6 weeks of fluoxetine, administered at 20 mg per day. Blood for fluoxetine and norfluoxetine plasma levels was drawn to ensure compliance. Tc99m HMPAO uptake was analyzed by the region of interest approach, normalized to the cerebellum, and by statistical parametric mapping (SPM). Results: No statistically significant differences between the two conditions were detected by both techniques. Correlation analysis between fluoxetine and norfluoxetine plasma levels and rCBF yielded no statistically significant values. Conclusion: Our findings suggest a differential effect of fluoxetine on CBF under the following conditions: (i) mental health versus psychiatric illness; (ii) acute versus long term administration. Our findings further emphasize the importance of longitudinal studies in elucidating the physiology of the normal brain as well as the pathophysiology of psychiatric disorders. |
| abstract_unstemmed |
Abstract Rationale: Of the specific serotonin reuptake inhibitors (SSRIs), fluoxetine is perhaps the most widely used. Anecdotal reports, mostly in the non-medical press, have suggested that it may positively affect psychological functioning and enhance quality of life in the absence of overt psychiatric disorder. Such widespread use is not supported by scientific data. Objective: This prospective single blind study examined the effects of long term administration of clinical doses of fluoxetine on cerebral blood flow (CBF) in healthy volunteers. Methods: Fifteen healthy subjects were examined by Tc99m HMPAO SPECT after 2 weeks of placebo administration and then after 6 weeks of fluoxetine, administered at 20 mg per day. Blood for fluoxetine and norfluoxetine plasma levels was drawn to ensure compliance. Tc99m HMPAO uptake was analyzed by the region of interest approach, normalized to the cerebellum, and by statistical parametric mapping (SPM). Results: No statistically significant differences between the two conditions were detected by both techniques. Correlation analysis between fluoxetine and norfluoxetine plasma levels and rCBF yielded no statistically significant values. Conclusion: Our findings suggest a differential effect of fluoxetine on CBF under the following conditions: (i) mental health versus psychiatric illness; (ii) acute versus long term administration. Our findings further emphasize the importance of longitudinal studies in elucidating the physiology of the normal brain as well as the pathophysiology of psychiatric disorders. |
| collection_details |
GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE |
| title_short |
Clinical doses of fluoxetine and cerebral blood flow in healthy volunteers |
| url |
http://dx.doi.org/10.1007/s002130050915 |
| remote_bool |
true |
| author2 |
Bonne, O. Krausz, Yodphat Aharon, Yitzhak Gelfin, Yevgenia Chisin, Roland Lerer, Bernard |
| author2Str |
Bonne, O. Krausz, Yodphat Aharon, Yitzhak Gelfin, Yevgenia Chisin, Roland Lerer, Bernard |
| ppnlink |
NLEJ188990615 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth |
| up_date |
2024-07-06T03:42:12.715Z |
| _version_ |
1803799581390012416 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ200735004</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20210706055915.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070527s1999 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ200735004</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Clinical doses of fluoxetine and cerebral blood flow in healthy volunteers</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1999</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">5</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Rationale: Of the specific serotonin reuptake inhibitors (SSRIs), fluoxetine is perhaps the most widely used. Anecdotal reports, mostly in the non-medical press, have suggested that it may positively affect psychological functioning and enhance quality of life in the absence of overt psychiatric disorder. Such widespread use is not supported by scientific data. Objective: This prospective single blind study examined the effects of long term administration of clinical doses of fluoxetine on cerebral blood flow (CBF) in healthy volunteers. Methods: Fifteen healthy subjects were examined by Tc99m HMPAO SPECT after 2 weeks of placebo administration and then after 6 weeks of fluoxetine, administered at 20 mg per day. Blood for fluoxetine and norfluoxetine plasma levels was drawn to ensure compliance. Tc99m HMPAO uptake was analyzed by the region of interest approach, normalized to the cerebellum, and by statistical parametric mapping (SPM). Results: No statistically significant differences between the two conditions were detected by both techniques. Correlation analysis between fluoxetine and norfluoxetine plasma levels and rCBF yielded no statistically significant values. Conclusion: Our findings suggest a differential effect of fluoxetine on CBF under the following conditions: (i) mental health versus psychiatric illness; (ii) acute versus long term administration. Our findings further emphasize the importance of longitudinal studies in elucidating the physiology of the normal brain as well as the pathophysiology of psychiatric disorders.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bonne, O.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Krausz, Yodphat</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Aharon, Yitzhak</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gelfin, Yevgenia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chisin, Roland</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lerer, Bernard</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">Psychopharmacology</subfield><subfield code="d">1959</subfield><subfield code="g">143(1999) vom: Jan., Seite 24-28</subfield><subfield code="w">(DE-627)NLEJ188990615</subfield><subfield code="w">(DE-600)2066933-1</subfield><subfield code="x">1432-2072</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:143</subfield><subfield code="g">year:1999</subfield><subfield code="g">month:01</subfield><subfield code="g">pages:24-28</subfield><subfield code="g">extent:5</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/s002130050915</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">143</subfield><subfield code="j">1999</subfield><subfield code="c">1</subfield><subfield code="h">24-28</subfield><subfield code="g">5</subfield></datafield></record></collection>
|
| score |
7.3980417 |